ADC 2018: Update on the Intranasal Insulin Trial II (INIT II) to Prevent Type 1 Diabetes
Data show that, while nasal insulin induced an immune response, it did not halt progression to T1D.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.